March 6, 2017
The Ministry of Health, Labor and Welfare (MHLW) on March 3 reported to its key advisory panel on its plan to approve the additional indication of head and neck cancer for Ono Pharmaceutical’s PD-1 inhibitor Opdivo (nivolumab), paving the way...read more